NeuBase Therapeutics Alpha and Beta Analysis
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as NeuBase Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in NeuBase Therapeutics over a specified time horizon. Remember, high NeuBase Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to NeuBase Therapeutics' market risk premium analysis include:
Beta 0.12 | Alpha (1.04) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
NeuBase |
NeuBase Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. NeuBase Therapeutics market risk premium is the additional return an investor will receive from holding NeuBase Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in NeuBase Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate NeuBase Therapeutics' performance over market.| α | -1.04 | β | 0.12 |
NeuBase Therapeutics Fundamentals Vs Peers
Comparing NeuBase Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NeuBase Therapeutics' direct or indirect competition across all of the common fundamentals between NeuBase Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as NeuBase Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NeuBase Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NeuBase Therapeutics to competition |
| Fundamentals | NeuBase Therapeutics | Peer Average |
| Return On Equity | -0.93 | -0.31 |
| Return On Asset | -0.43 | -0.14 |
| Current Valuation | (5.83 M) | 16.62 B |
| Shares Outstanding | 3.75 M | 571.82 M |
| Shares Owned By Insiders | 13.37 % | 10.09 % |
| Shares Owned By Institutions | 12.68 % | 39.21 % |
| Number Of Shares Shorted | 15.57 K | 4.71 M |
NeuBase Therapeutics Opportunities
NeuBase Therapeutics Return and Market Media
The Stock received some media coverage during the period.About NeuBase Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including NeuBase or other delisted stocks. Alpha measures the amount that position in NeuBase Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
NeuBase Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of NeuBase Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeuBase Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of NeuBase Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of NeuBase Therapeutics. Please utilize our Beneish M Score to check the likelihood of NeuBase Therapeutics' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 30th of September 2023 Last Quarter Report | View |
Build Portfolio with NeuBase Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |